Tanikawa Kyuichi
International Institute for Liver Research, Kurume Research Center, 2432-3 Aikawa-machi, Kurume 839-0861, Japan.
Hepatobiliary Pancreat Dis Int. 2004 Feb;3(1):17-20.
Few comprehensive reviews on the pathogenesis of hepatitis C virus (HCV)-related liver diseases have been presented to the present. This article was to review the pathogenesis and treatment of HCV-related liver diseases.
Data presented here are mostly taken from Japanese studies.
HCV infection is characterized by persistent inflammation of the liver and frequent development of hepatocellular carcinoma (HCC) in most cases. These characteristic evidences could be explained by immunological alterations and oxidative stress in the hepatocyte caused by HCV infection. Interferon (IFN) treatment is carried out, at present, not only for the elimination of infected HCV for the treatment of chronic liver diseases, but also for both the prevention of HCC and the treatment of advanced HCC with chemotherapy. The treatment for oxidative stress is also important for non-responders to IFN.
It is important to understand the pathogenesis of HCV-related liver diseases for a successful treatment.
目前关于丙型肝炎病毒(HCV)相关肝病发病机制的全面综述较少。本文旨在综述HCV相关肝病的发病机制及治疗方法。
此处呈现的数据大多取自日本的研究。
HCV感染的特征是肝脏持续炎症,且在大多数情况下肝细胞癌(HCC)的发生率较高。这些特征性证据可以通过HCV感染引起的肝细胞免疫改变和氧化应激来解释。目前,干扰素(IFN)治疗不仅用于清除感染的HCV以治疗慢性肝病,还用于预防HCC以及联合化疗治疗晚期HCC。对于IFN无反应者,氧化应激治疗也很重要。
了解HCV相关肝病的发病机制对于成功治疗至关重要。